BRPI0711354A2 - composto método de sintetizar um composto, uso de um composto, método de profilaxia ou tratamento de infecção viral, e, composição farmacêutica - Google Patents

composto método de sintetizar um composto, uso de um composto, método de profilaxia ou tratamento de infecção viral, e, composição farmacêutica Download PDF

Info

Publication number
BRPI0711354A2
BRPI0711354A2 BRPI0711354-4A BRPI0711354A BRPI0711354A2 BR PI0711354 A2 BRPI0711354 A2 BR PI0711354A2 BR PI0711354 A BRPI0711354 A BR PI0711354A BR PI0711354 A2 BRPI0711354 A2 BR PI0711354A2
Authority
BR
Brazil
Prior art keywords
compound
formula
valine
compound according
treatment
Prior art date
Application number
BRPI0711354-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Christopher Mcguigan
Jan Balzarini
Marco Migliore
Original Assignee
Univ Cardiff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cardiff filed Critical Univ Cardiff
Publication of BRPI0711354A2 publication Critical patent/BRPI0711354A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0711354-4A 2006-05-09 2007-05-09 composto método de sintetizar um composto, uso de um composto, método de profilaxia ou tratamento de infecção viral, e, composição farmacêutica BRPI0711354A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0609178.9 2006-05-09
GBGB0609178.9A GB0609178D0 (en) 2006-05-09 2006-05-09 Novel compounds
PCT/GB2007/001677 WO2007129083A1 (en) 2006-05-09 2007-05-09 Anti-viral pyrimidine nucleoside derivatives

Publications (1)

Publication Number Publication Date
BRPI0711354A2 true BRPI0711354A2 (pt) 2011-09-27

Family

ID=36637171

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711354-4A BRPI0711354A2 (pt) 2006-05-09 2007-05-09 composto método de sintetizar um composto, uso de um composto, método de profilaxia ou tratamento de infecção viral, e, composição farmacêutica

Country Status (22)

Country Link
US (3) US8329664B2 (enExample)
EP (1) EP2016081B1 (enExample)
JP (1) JP5261374B2 (enExample)
KR (1) KR101447522B1 (enExample)
CN (1) CN101443332B (enExample)
AT (1) ATE506367T1 (enExample)
AU (1) AU2007246814B2 (enExample)
BR (1) BRPI0711354A2 (enExample)
CA (1) CA2656780C (enExample)
CY (1) CY1111711T1 (enExample)
DE (1) DE602007014030D1 (enExample)
DK (1) DK2016081T3 (enExample)
EA (1) EA015178B1 (enExample)
ES (1) ES2365057T3 (enExample)
GB (1) GB0609178D0 (enExample)
IL (1) IL194806A (enExample)
NZ (1) NZ573377A (enExample)
PL (1) PL2016081T3 (enExample)
PT (1) PT2016081E (enExample)
SI (1) SI2016081T1 (enExample)
TW (1) TWI385172B (enExample)
WO (1) WO2007129083A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0009486D0 (en) * 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB2452556A (en) * 2007-09-07 2009-03-11 Univ Leuven Kath Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus
JP2013539760A (ja) * 2010-10-09 2013-10-28 シナジー ファーマシューティカルズ インコーポレイテッド 抗ウイルス化合物およびその有用な中間体の調製方法
CN102443032B (zh) * 2010-10-09 2015-07-22 英希比泰克斯公司 制备抗病毒组合物的方法及其中间体的应用
MD4110C1 (ro) * 2010-10-21 2011-12-31 Валериу РУДИК Preparat antiherpetiс
KR101875997B1 (ko) * 2015-05-04 2018-07-06 엔 앤드 엔 파마세우티칼스 인크. 엔-메탄노카르바티미딘을 이용한 대상포진의 치료방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62255499A (ja) 1986-04-28 1987-11-07 Teijin Ltd 螢光性ヌクレオシド又はヌクレオチド
EP0346108A3 (en) 1988-06-09 1991-04-24 The Wellcome Foundation Limited Anti-infective nucleosides
YU43193A (sh) 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
GB9716231D0 (en) 1997-07-31 1997-10-08 Amersham Int Ltd Base analogues
HK1053126A1 (zh) 1999-07-22 2003-10-10 新生物生物公司 酶催化的治疗活化
IL147749A0 (en) 1999-07-22 2002-08-14 Newbiotics Inc Methods for treating therapy-resistant tumors
JP2003527317A (ja) 1999-07-22 2003-09-16 ニューバイオティックス インコーポレイテッド 酵素触媒抗感染性治療剤
GB0009486D0 (en) 2000-04-17 2000-06-07 Univ Cardiff Chemical compounds
GB0011203D0 (en) * 2000-05-09 2000-06-28 Univ Cardiff Chemical compounds
MY141594A (en) * 2000-06-15 2010-05-14 Novirio Pharmaceuticals Ltd 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
AU2003247084B9 (en) * 2002-06-28 2018-07-26 Centre National De La Recherche Scientifique Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
US7582748B2 (en) * 2003-03-20 2009-09-01 Microbiologica Quimica E Farmaceutical Ltd. Methods of manufacture of 2′-deoxy-β-L-nucleosides
US20050137141A1 (en) 2003-10-24 2005-06-23 John Hilfinger Prodrug composition
AU2004320625B2 (en) 2004-06-07 2009-08-27 Anadys Pharmaceuticals, Inc. 3-beta-D-ribofuranosylthiazolo[4,5-d]pyrimidine nucleosides and uses thereof

Also Published As

Publication number Publication date
US20100222295A1 (en) 2010-09-02
PT2016081E (pt) 2011-06-28
EA200870505A1 (ru) 2009-04-28
US20150072948A1 (en) 2015-03-12
PL2016081T3 (pl) 2011-12-30
TWI385172B (zh) 2013-02-11
DK2016081T3 (da) 2011-06-20
CA2656780C (en) 2015-04-28
US8859512B2 (en) 2014-10-14
IL194806A0 (en) 2009-09-22
SI2016081T1 (sl) 2011-09-30
CN101443332A (zh) 2009-05-27
CN101443332B (zh) 2011-11-09
AU2007246814A1 (en) 2007-11-15
EA015178B1 (ru) 2011-06-30
US8329664B2 (en) 2012-12-11
NZ573377A (en) 2011-03-31
ES2365057T3 (es) 2011-09-21
EP2016081B1 (en) 2011-04-20
TW200813066A (en) 2008-03-16
EP2016081A1 (en) 2009-01-21
AU2007246814B2 (en) 2012-07-19
US9427447B2 (en) 2016-08-30
JP5261374B2 (ja) 2013-08-14
DE602007014030D1 (de) 2011-06-01
WO2007129083A1 (en) 2007-11-15
US20130096079A1 (en) 2013-04-18
KR20090042204A (ko) 2009-04-29
CY1111711T1 (el) 2015-10-07
KR101447522B1 (ko) 2014-10-06
JP2009536188A (ja) 2009-10-08
ATE506367T1 (de) 2011-05-15
IL194806A (en) 2015-08-31
GB0609178D0 (en) 2006-06-21
CA2656780A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
JP4923216B2 (ja) 化合物
JP5271913B2 (ja) 化合物
ES2246247T3 (es) Derivados de sulfonil-carboxamida procedimiento para su preparacion y su utilizacion como medicamentos.
ES2657687T3 (es) Derivados de pirrolopirimidina para uso en el tratamiento de infecciones virales
JP2002525374A (ja) 抗ウイルスプリン誘導体
JP2013540129A (ja) がん治療で使用するためのゲムシタビンのアミド亜リン酸エステル誘導体
US9427447B2 (en) Anti-viral pyrimidine nucleoside derivatives
CA2271299A1 (en) Benzoheterocyclic distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
KR102502749B1 (ko) 간 전달 엔테카비어 프로드러그 뉴클레오티드 시클로 포스페이트 화합물 및 응용
ITMI951450A1 (it) Esteri acilici di amminoacidi achirali di gangiclovir e relativi derivati
US20110184003A1 (en) Compounds and methods for the treatment of viral infection
BR112021013730A2 (pt) Composto de sulfiamidina amida-arilamida cíclica interna e uso do mesmo para tratamento de hepatite b
GB2452556A (en) Nucleoside analogues esterified at 3 and/or 5 positions by neutral non-polar amino acid, or oligopeptide thereof, for combating Varicella Zoster virus
ES2829254T3 (es) Nucleósidos de pirrolopirimidina y análogos de los mismos útiles como agentes antivíricos
CN119462821A (zh) 新型GalNAc的靶向递送片段及其制备和应用
WO2023230472A1 (en) Inhibitors of molluscum contagiosum infection and methods using the same
EP4284514A1 (en) Heteroaromatic phosphonium salts and their use treating cancer
CN118084819A (zh) 噻唑类衍生物及其在治疗白血病中的应用

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2513 DE 06-03-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.